Evidence map›Paper›PMID 19010865›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2008

The use of genetic markers to identify lung cancer in fine needle aspiration samples.

Rajbir K Gill, Madeline F Vazquez, Arin Kramer, Megan Hames, Lijuan Zhang, Kerstin Heselmeyer-Haddad, Thomas Ried, Konstantin Shilo, Claudia Henschke, David Yankelevitz and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Strategic Initiatives for Veterans with Lung Cancer.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2020
    Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Rajbir K GillLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Madeline F Vazquez
Arin Kramer
Megan Hames
Lijuan Zhang
Kerstin Heselmeyer-Haddad
Thomas Ried
Konstantin Shilo
Claudia Henschke
David Yankelevitz
Jin Jen
Pancreatic Cancer Action Network · USNational Cancer Institute · USArmed Forces Institute of Pathology · US

Funding

Intratumor heterogeneity and tumor evolutionZIABC010834 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RIED, THOMAS · 2009 to 2023
$12.2M
Identifying Diagnostic Markers for Cervical Cancer, Breast Cancer, and Prostate Z01BC010834 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RIED, THOMAS · 2007 to 2008
$1.3M
Identification of genes differentially expressed in lungZ01CP010163 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI JEN, JIN · 2001 to 2008
$848k
Intramural NIH HHS Z01 CP010163
6 · The paper itself

Abstract

purposeWe seek to establish a genetic test to identify lung cancer using cells obtained through computed tomography-guided fine needle aspiration (FNA). EXPERIMENTAL

designWe selected regions of frequent copy number gains in chromosomes 1q32, 3q26, 5p15, and 8q24 in non-small cell lung cancer and tested their ability to determine the neoplastic state of cells obtained by FNA using fluorescent in situ hybridization. Two sets of samples were included. The pilot set included six paraffin-embedded, noncancerous lung tissues and 33 formalin-fixed FNA specimens. These 39 samples were used to establish the optimal fixation and single scoring criteria for the samples. The test set included 40 FNA samples. The results of the genetic test were compared with the cytology, pathology, and clinical follow-up for each case to assess the sensitivity and specificity of the genetic test.

resultsNontumor lung tissues had < or= 4 signals per nucleus for all tested markers, whereas tumor samples had > or = 5 signals per nucleus in five or more cells for at least one marker. Among the 40 testing cases, 36 of 40 (90%) FNA samples were analyzable. Genetic analysis identified 15 cases as tumor and 21 cases as nontumor. Clinical and pathologic diagnoses confirmed the genetic test in 15 of 16 lung cancer cases regardless of tumor subtype, stage, or size and in 20 of 20 cases diagnosed as benign lung diseases.

conclusionsA set of only four genetic markers can distinguish the neoplastic state of lung lesion using small samples obtained through computed tomography-guided FNA.

Indexed as

Biopsy, NeedleAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungChromosome AberrationsFemaleHumansIn Situ Hybridization, FluorescenceLung NeoplasmsMaleMicroscopy, FluorescenceMiddle AgedSensitivity and SpecificitySurgery, Computer-AssistedBiomarkers, Tumor

Identifiers

PMID19010865
PMCPMC2586966
OpenAlexW2166777583

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.